Jason Hawkes, MD, MS, discusses recent advances in the management of chronic spontaneous urticaria, focusing on the transition to new targeted therapies.

Jason Hawkes, MD, MS, outlines key factors influencing the selection between biologics, oral small molecules, and traditional systemic therapies in CSU management.

Jason Hawkes, MD, MS, reviews long-term efficacy and safety data for remibrutinib in the management of chronic spontaneous urticaria.

Jason Hawkes, MD, MS discusses strategies for addressing patient hesitancy regarding oral versus injectable therapies in the treatment of CSU.

Jason Hawkes, MD, MS examines how adherence, patient expectations, and access barriers influence management and treatment sequencing in CSU.

Jason Hawkes, MD, MS details the clinical advantages and patient populations best suited for oral BTK inhibitor therapy, such as remibrutinib, in CSU.

Jason Hawkes, MD, MS, explains how updated treatment guidelines are incorporating remibrutinib as a key option for CSU after antihistamine failure.

Jason Hawkes, MD, MS, discusses emerging biomarkers and clinical characteristics that may help identify patients most likely to benefit from remibrutinib in CSU.

Jason Hawkes, MD, MS, envisions the future of CSU management, highlighting the integration of precision medicine and targeted therapies to individualize care.